Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REMIFENTANIL vs REPOTRECTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REMIFENTANIL vs REPOTRECTINIB: Safety Overview

Metric REMIFENTANIL REPOTRECTINIB
Total FAERS Reports 2,733 187
Deaths Reported 210 27
Death Rate 7.7% 14.4%
Hospitalizations 995 48
Average Patient Age 50.3 yrs 60.8 yrs
% Female Patients 48.2% 61.1%
FDA Approval Date Jan 16, 2018 Jun 11, 2024
Manufacturer Fresenius Kabi USA, LLC E.R. Squibb & Sons, L.L.C.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription